ALNY Jun 2024 135.000 put
- Barrons.com
Alnylam Stock Soars After Positive Results From Heart Disease Study
The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.
- Bloomberg
Alnylam Soars After Drug Meets Goal in Heart Disease Trial
(Bloomberg) -- Alnylam Pharmaceuticals Inc. shares soared after its drug succeeded in treating a progressive and deadly form of heart disease, potentially opening up a new avenue for the company’s top-selling product. Most Read from BloombergHow Long Can High Rates Last? Bond Markets Say Maybe ForeverNvidia Sales Grow So Fast That Wall Street Can’t Keep UpJain Raises $5.3 Billion in Biggest Hedge Fund Debut Since 2018Russia Is Storing Up a Crime Wave When Its War on Ukraine EndsNasdaq Futures Un
- Investor's Business Daily
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
